Literature DB >> 2817866

Penetration of ciprofloxacin into saliva and nasal secretions and effect of the drug on the oropharyngeal flora of ill subjects.

E A Piercy1, R E Bawdon, P A Mackowiak.   

Abstract

The pharmacokinetics of ciprofloxacin and its effect on the oropharyngeal bacterial flora were examined in 21 ill patients being treated for methicillin-resistant Staphylococcus aureus infections or colonization or both. Oral ciprofloxacin (750 mg twice a day) produced peak and trough concentrations in serum of 2.56 +/- 1.80 and 0.97 +/- 0.81 micrograms/ml and steady-state salivary and nasal secretory concentrations of 1.29 +/- 1.0 and 1.84 +/- 0.91 micrograms/ml, respectively. Because of technical problems, nasal secretory concentrations were felt to represent rough approximations of true values. Oral ciprofloxacin therapy did not promote colonization of the oropharynx by gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817866      PMCID: PMC172724          DOI: 10.1128/AAC.33.9.1645

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections.

Authors:  E A Piercy; D Barbaro; J P Luby; P A Mackowiak
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

2.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

3.  Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization.

Authors:  M E Mulligan; P J Ruane; L Johnston; P Wong; J P Wheelock; K MacDonald; J F Reinhardt; C C Johnson; B Statner; I Blomquist
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.

Authors:  B Joos; B Ledergerber; M Flepp; J D Bettex; R Lüthy; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

5.  Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.

Authors:  M A Gonzalez; F Uribe; S D Moisen; A P Fuster; A Selen; P G Welling; B Painter
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

6.  Tissue penetration of ciprofloxacin after single and multiple doses.

Authors:  M LeBel; F Vallée; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

7.  Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora.

Authors:  T Bergan; C Delin; S Johansen; I M Kolstad; C E Nord; S B Thorsteinsson
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

  7 in total
  3 in total

1.  Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States.

Authors:  D F Sahm; D E Peterson; I A Critchley; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

2.  In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator.

Authors:  Hung-Jen Tang; Wen-Chien Ko; Chi-Chung Chen; Po-Lin Chen; Han Siong Toh; Tzu Chieh Weng; Wen-Liang Yu; Shyh-Ren Chiang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

3.  Membrane Transporters in Human Parotid Gland-Targeted Proteomics Approach.

Authors:  Joanna Lapczuk-Romanska; Diana Busch; Ewa Gieruszczak; Agnieszka Drozdzik; Katarzyna Piotrowska; Robert Kowalczyk; Stefan Oswald; Marek Drozdzik
Journal:  Int J Mol Sci       Date:  2019-09-28       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.